الفهرس 
The effect of sodium glucose transporter 2 inhibitor Empagliflozin on albuminuria and kidney function progression in patients with non diabetic glomerulonephritis
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 112 |  |  |
| | | from | 112 | | |
Abstract
Background: Nearly all forms of acute glomerulonephritis have a tendency to progress
to chronic glomerulonephritis. The condition is characterized by irreversible and
progressive glomerular and tubulointerstitial fibrosis, ultimately leading to a reduction in
the glomerular filtration rate (GFR) and retention of uremic toxins. If disease progression
is not halted with therapy, the net results are chronic kidney disease (CKD), end-stage
renal disease (ESRD), and cardiovascular disease (Couser, 2001).
Aim of the study: examine The effect of sodium glucose transporter 2 inhibitor
Empagliflozin on albuminuria and kidney function progression in patients with non
diabetic glomerulonephritis.